The Utility of the Liverpool Adverse Drug Reaction Assessment Tools in the Evaluation of Chemotherapy-Induced Nausea and Vomiting in Children

Introduction: Chemotherapy-induced nausea and vomiting (CINV) are common adverse drug reactions (ADR) experienced by children undergoing treatment for cancer. New paediatric ADR Assessment Causality and Avoidability tools (LCAT and LAAT) of Liverpool are suitable for categorizing factors related to ADR prevention and improving patient care. Still, no studies to date have compared the utility and results of its application for CINV in countries with different levels of development. Objective: To investigate the utility of the Liverpool Adverse Drug Reaction Causality and Avoidability Assessment Tools (LCAT and LAAT) in assessing CINV in children. Method: Prospective observational study of CINV assessment in children aged 4 to 16 years from Alder Hey Children’s Hospital (Liverpool, UK) and “Instituto de Puericultura e Pediatria Martagão Gesteira” (Rio de Janeiro, Brazil). Children (helped by the parents) completed a symptom diary during chemotherapy and for 24 hours after treatment. Information regarding underlying diagnosis, past medical history, and medications administered was collected from the patient record. Case reports were prepared, and the temporal relationship between nausea and vomiting and exposure to chemotherapy, including any strategy to prevent CINV, was recorded. The causality and avoidability were assessed with LCAT and LAAT, respectively. Results: There were 26 reports of CINV in 36 chemotherapy cycles. The causality assessment was ‘definite’ for 24 cases. Twenty ADRs were deemed ‘definitely avoidable’ and four ‘not avoidable’. Selection of inappropriate therapeutic options and non-administration of antiemetic were the most common factors observed in the hospitals studied. Conclusion: The LCAT and LAAT were helpful for assessing CINV in children in two different hospitals.

[1]  Anna Evans,et al.  Nausea in Numbers: Electronic Medical Record Nausea and Vomiting Assessment for Children With Cancer , 2020, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.

[2]  C. Weng,et al.  Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults , 2020, Supportive Care in Cancer.

[3]  H. Patel,et al.  Improving medication safety in oncology care: impact of clinical pharmacy interventions on optimizing patient safety , 2019, International Journal of Clinical Pharmacy.

[4]  C. Portwine,et al.  Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline , 2019, Pediatric blood & cancer.

[5]  Iman Zaghloul,et al.  Pharmacovigilance in developing countries (part I): importance and challenges , 2018, International Journal of Clinical Pharmacy.

[6]  Delivering Quality Health Services: A Global Imperative , 2018 .

[7]  J. Polesel,et al.  Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance , 2018, International Journal of Clinical Pharmacy.

[8]  C. Portwine,et al.  Guideline for the prevention of acute chemotherapy‐induced nausea and vomiting in pediatric cancer patients: A focused update , 2017, Pediatric blood & cancer.

[9]  M. Sancar,et al.  Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life , 2016, International Journal of Clinical Pharmacy.

[10]  Rakesh Kb,et al.  A Retrospective Evaluation of Adverse Drug Reactions Due to Cancer Chemotherapy in a Tertiary Care Hospital in South India , 2016 .

[11]  Faith Gibson,et al.  Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood. , 2016, The Cochrane database of systematic reviews.

[12]  M. Pirmohamed,et al.  Development of the Liverpool Adverse Drug Reaction Avoidability Assessment Tool , 2015, PloS one.

[13]  Sten Olsson,et al.  Pharmacovigilance in resource-limited countries , 2015, Expert review of clinical pharmacology.

[14]  A. del Giglio,et al.  Assessment of adherence to the guidelines for the management of nausea and vomiting induced by chemotherapy , 2015, Einstein.

[15]  M. Pirmohamed,et al.  ADRIC: Adverse Drug Reactions In Children – a programme of research using mixed methods , 2014 .

[16]  H. Vashani,et al.  The effect of massage therapy on chemotherapy-induced nausea and vomiting in pediatric cancer , 2013, Iranian journal of nursing and midwifery research.

[17]  M. Aapro,et al.  Prevention of Nausea and Vomiting in Cancer Patients , 2013 .

[18]  M. Pirmohamed,et al.  Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children – a prospective observational cohort study of 6,601 admissions , 2013, BMC Medicine.

[19]  M. Pirmohamed,et al.  Development and Inter-Rater Reliability of the Liverpool Adverse Drug Reaction Causality Assessment Tool , 2011, PloS one.

[20]  K. Bull,et al.  A longitudinal study of the quality of life of children treated for a medulloblastoma or a low-grade cerebellar astrocytoma compared with healthy controls: report of cross-sectional data at the first assessment , 2008 .

[21]  E. Antonarakis,et al.  Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice , 2004, Archives of Disease in Childhood.

[22]  Bains,et al.  Adverse Drug Reaction Assessment Tools for Children , 2023 .

[23]  J. Lerman,et al.  Pharmacokinetics and Pharmacology of Drugs Used in Children , 2019, A Practice of Anesthesia for Infants and Children.

[24]  L. Dupuis,et al.  2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children , 2016, Supportive Care in Cancer.

[25]  A. Jatoi,et al.  Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2,388 health care providers , 2014, Supportive Care in Cancer.

[26]  B. Hugman,et al.  From the Uppsala Monitoring Centre , 2005, Drug safety.